Black Diamond Therapeutics

BDTXNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$113.758 M

$1.98 +1.54%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

$22.4B

#17 by earnings

Shares outstanding

57,453,747

Latest filing cover page

P/E ratio

0.0

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#110enGene TherapeuticsENGN$137.4M
#111LENZ TherapeuticsLENZ$129.8M
#112Black Diamond TherapeuticsBDTX$113.8M
#113Cardiff OncologyCRDF$103.5M
#114Cognition TherapeuticsCGTX$93.3M

What if Black Diamond Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$526,231.47

Per share 265,773× higher

Bitcoin $1.74T

$30,314.04

Per share 15,310× higher

Nvidia $5.52T

$96,003.61

Per share 48,487× higher

Or at a round number

$200.0M $500.0M $1.00B $2.00B

Where these numbers come from

Share counts and financials for Black Diamond Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.